162 related articles for article (PubMed ID: 17683176)
1. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot.
Pivot X
Drugs; 2007; 67(12):1800-1. PubMed ID: 17683176
[No Abstract] [Full Text] [Related]
2. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles.
Miles D
Drugs; 2007; 67(12):1800-1. PubMed ID: 17683177
[No Abstract] [Full Text] [Related]
3. Biomarkers in breast cancer.
McArthur HL; Dickler MN
Cancer Biol Ther; 2008 Jan; 7(1):21-2. PubMed ID: 18347421
[No Abstract] [Full Text] [Related]
4. Bevacizumab in the treatment of breast cancer.
Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Mayer EL; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
[TBL] [Abstract][Full Text] [Related]
6. [Anti-VEGF therapy with bevacizumab in breast cancer].
Tóth J; Gonda A; Szántó J
Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.
Lyseng-Williamson KA; Robinson DM
BioDrugs; 2006; 20(3):193-5. PubMed ID: 16724868
[TBL] [Abstract][Full Text] [Related]
8. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
de Gramont A; Van Cutsem E
Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis - still a worthwhile target for breast cancer therapy?
Lord S; Harris AL
Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S19. PubMed ID: 21172081
[No Abstract] [Full Text] [Related]
10. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
Damasceno M
Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic agents in breast cancer.
Salter JT; Miller KD
Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
[No Abstract] [Full Text] [Related]
12. The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer.
Keefe SM; Demichele A
Curr Oncol Rep; 2010 Jan; 12(1):22-5. PubMed ID: 20425604
[TBL] [Abstract][Full Text] [Related]
13. [Bevacizumab and radiotherapy].
Blanchard P; Besse B; Deutsch E
Rev Mal Respir; 2008 Dec; 25(10):1319-21. PubMed ID: 19107021
[No Abstract] [Full Text] [Related]
14. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab for advanced breast cancer.
Traina TA; Rugo HS; Dickler M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
[TBL] [Abstract][Full Text] [Related]
17. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
Marty M; Pivot X
Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
[TBL] [Abstract][Full Text] [Related]
18. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer F; Gampenrieder SP; Schlattau A; Greil R
Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
[No Abstract] [Full Text] [Related]
19. Caution in adding bevacizumab in the adjuvant treatment of breast cancer.
Ziogas D; Roukos D
Ann Surg Oncol; 2010 Feb; 17(2):653-4; author reply 655-6. PubMed ID: 19888632
[No Abstract] [Full Text] [Related]
20. FDA and Avastin: crossroads in an era of targeted therapies.
Tripathy D
Oncology (Williston Park); 2010 Oct; 24(11):989-90. PubMed ID: 21155445
[No Abstract] [Full Text] [Related]
[Next] [New Search]
